Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its earnings results on Monday. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.01, FiscalAI reports. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The firm had revenue of $17.16 million for the quarter, compared to the consensus estimate of $17.03 million.

Enanta Pharmaceuticals Trading Up 0.8%

ENTA stock traded up $0.12 on Monday, hitting $15.46. 282,502 shares of the company’s stock traded hands, compared to its average volume of 184,785. The stock has a market cap of $448.63 million, a price-to-earnings ratio of -4.83 and a beta of 1.01. Enanta Pharmaceuticals has a 1-year low of $5.03 and a 1-year high of $17.15. The stock has a fifty day moving average of $13.61 and a 200-day moving average of $13.42.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ENTA. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.29.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently modified their holdings of the stock. Man Group plc boosted its holdings in shares of Enanta Pharmaceuticals by 9.2% in the fourth quarter. Man Group plc now owns 43,847 shares of the biotechnology company’s stock worth $691,000 after buying an additional 3,691 shares during the period. Informed Momentum Co LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at approximately $646,000. Invesco Ltd. lifted its position in shares of Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 2,607 shares in the last quarter. Deutsche Bank AG boosted its stake in Enanta Pharmaceuticals by 4.6% in the 4th quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,055 shares during the period. Finally, Headlands Technologies LLC purchased a new position in Enanta Pharmaceuticals during the 4th quarter worth approximately $356,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.